Paroxetine Hydrochloride

• CAT Number: A000195
• CAS Number: 78246-49-8
• Molecular Formula: C19H21ClFNO3
• Molecular Weight: 365.3
• Purity: ≥95%
• Target: AChR
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• InChI: 1S/C19H20FNO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7-8,10-12H2;1H/t14-,17-;/m0./s1
• InChIKey: GELRVIPPMNMYGS-RVXRQPKJSA-N
• SMILES: C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.Cl

Paroxetine hydrochloride is a serotonin uptake inhibitor that is effective in the treatment of depression. It is a highly potent and selective ST (serotonin transporter/5-HT) uptake inhibitor. It acts by binding to ST (serotonin transporter/SERT) with high affinity. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Paroxetine HCl has also displayed a high affinity for muscarinic acetylcholine receptors.

Reference

1: Brittain HG. Paroxetine hydrochloride: polymorphs and solvatomorphs. Profiles
Drug Subst Excip Relat Methodol. 2013;38:407-21. doi:
10.1016/B978-0-12-407691-4.00009-5. Review. PubMed PMID: 23668409.

2: Germann D, Ma G, Han F, Tikhomirova A. Paroxetine hydrochloride. Profiles Drug
Subst Excip Relat Methodol. 2013;38:367-406. doi:
10.1016/B978-0-12-407691-4.00008-3. Review. PubMed PMID: 23668408.

3: Khatavkar UN, Shimpi SL, Jayaram Kumar K, Deo KD. Development and comparative
evaluation of in vitro, in vivo properties of novel controlled release
compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™
platform technology. Drug Dev Ind Pharm. 2013 Aug;39(8):1175-86. doi:
10.3109/03639045.2012.682222. Epub 2012 May 21. PubMed PMID: 22607046.

4: Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS. Paroxetine mesylate:
comparable to paroxetine hydrochloride? Expert Opin Pharmacother. 2010
Feb;11(2):185-93. doi: 10.1517/14656560903451708. Review. PubMed PMID: 20088740.

5: Jin SJ, Yoo YH, Kim MS, Kim JS, Park JS, Hwang SJ. Paroxetine hydrochloride
controlled release POLYOX matrix tablets: screening of formulation variables
using Plackett-Burman screening design. Arch Pharm Res. 2008 Mar;31(3):399-405.
doi: 10.1007/s12272-001-1170-0. Epub 2008 Apr 13. PubMed PMID: 18409056.

6: Venkatachalam A, Chatterjee VS. Stability-indicating high performance thin
layer chromatography determination of Paroxetine hydrochloride in bulk drug and
pharmaceutical formulations. Anal Chim Acta. 2007 Aug 29;598(2):312-7. Epub 2007
Aug 8. PubMed PMID: 17719907.

7: Alarfaj N, Razeq SA, Sultan M. Spectrofluorimetric determination of paroxetine
hydrochloride in its formulations and human plasma. Chem Pharm Bull (Tokyo). 2006
Apr;54(4):564-6. PubMed PMID: 16595967.

8: Onal A, Kepekçi SE, Oztunç A. Spectrophotometric methods for the determination
of the antidepressant drug paroxetine hydrochloride in tablets. J AOAC Int. 2005
Mar-Apr;88(2):490-5. PubMed PMID: 15859076.

9: Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow
P, Qazi R, Smith B. Effect of paroxetine hydrochloride (Paxil) on fatigue and
depression in breast cancer patients receiving chemotherapy. Breast Cancer Res
Treat. 2005 Feb;89(3):243-9. PubMed PMID: 15754122.

10: Erk N, Biryol I. Voltammetric and HPLC techniques for the determination of
paroxetine hydrochloride. Pharmazie. 2003 Oct;58(10):699-704. PubMed PMID:
14609280.